Pfizer (PFE) CEO Albert Bourla is betting big on repeating the success of its COVID-19 vaccine with an experimental oral treatment — and he's putting the company's money where its mouth is. Bourla told Yahoo Finance Wednesday the company is committing $1 billion to develop the oral treatment — a protease inhibitor — which would give the world an easy-to-use, targeted treatment, hopefully by year's end. The current market for COVID-19 treatments includes monoclonal antibodies and some repurposed drugs, including generics and Gilead Sciences' (GILD) Veklury (formerly Remdesivir) - all of which require being in a hospital or clinic to...